The adverse effects with ibuprofen after major orthopedic surgeries: A protocol for the PERISAFE randomized clinical trial
- PMID: 39887674
- DOI: 10.1111/aas.14578
The adverse effects with ibuprofen after major orthopedic surgeries: A protocol for the PERISAFE randomized clinical trial
Abstract
Introduction: Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended for pain treatment after elective hip and knee arthroplasties. However, evidence regarding the incidence of adverse effects with short-term NSAID treatment following surgery is limited. We, therefore, aim to assess the adverse effects with an eight-day postoperative treatment with ibuprofen after elective hip and knee arthroplasties.
Methods and analysis: PERISAFE is a randomized, placebo-controlled, blinded multicenter trial with 90-day and one-year follow-up. Eligible patients undergoing elective hip or knee arthroplasty are allocated 1:1 to either ibuprofen 400 mg ×3/day or identical placebo ×3/day for eight days after surgery. The primary outcome is a composite of either death, acute myocardial infarction, stroke, pulmonary embolism, deep venous thrombosis, renal failure, major bleeding, re-operation, gastrointestinal ulcer, or readmission within 90 days postoperatively. Secondary outcomes are hospital-free days within 90 days postoperatively, a composite of ibuprofen and opioid-related adverse reactions based on eight-day postoperative diary, and health related quality of life after 90 days postoperatively. A total of 2904 patients are needed to demonstrate a relative risk reduction of 33% in the placebo group, accepting a risk of type I error of 5% and type II error of 20% and a proportion of serious adverse events in the ibuprofen group of 8%. The primary analysis will be in the modified intention-to-treat population.
Ethics and dissemination: The trial is approved by the Danish Medicine Agency and the Research Ethics Committee (EU CT no. 2022-502, 502-32-00). We plan to submit for publication in a major international peer-reviewed journal and present results at scientific meetings.
Keywords: adverse effects; analgesic treatment; arthroplasty; hip arthroplasty; ibuprofen; knee arthroplasty; nsaid; pain treatment; total hip arthroplasty surgery; total knee arthroplasty surgery; unicompartment knee arthroplasty.
© 2025 Acta Anaesthesiologica Scandinavica Foundation.
References
REFERENCES
-
- Ethgen O, Bruyère O, Richy F, Dardennes C, Reginster JY. Health‐related quality of life in Total hip and Total knee arthroplasty. J Bone Jt Surg Am. 2004;86(5):963‐974.
-
- Rupp M, Lau E, Kurtz SM, Alt V. Projections of primary TKA and THA in Germany from 2016 through 2040. Clin Orthop Relat Res. 2020;478(7):1622‐1633.
-
- Inacio MCS, Graves SE, Pratt NL, Roughead EE, Nemes S. Increase in Total joint arthroplasty projected from 2014 to 2046 in Australia: a conservative local model with international implications. Clin Orthop Relat Res. 2017;475(8):2130‐2137.
-
- Sloan M, Premkumar A, Sheth NP. Projected volume of primary Total joint arthroplasty in the U.S., 2014 to 2030. J Bone Jt Surg Am. 2018;100(17):1455‐1460.
-
- Singh JA, Lewallen DG. Ninety‐day mortality in patients undergoing elective Total hip or Total knee arthroplasty. J Arthroplast. 2012;27(8):1417‐1422.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
